Rakuten TV and Samsung TV Plus Reinforce Solid Partnership by Launching Over 166 Channels in 16 Markets
20.4.2021 11:30:00 EEST | Business Wire | Press release
Rakuten TV strengthens its ongoing partnership with Samsung Electronics to expand its free content offering on the platform’s AVOD (Advertising-Video-on-Demand) service and launches over 20 of the platform's own and third-party channels on the Samsung TV Plus service across 16 European markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005300/en/
TV Plus Interface (Graphic: Business Wire)
This launch opens new opportunities for advertisers to get in front of audiences across the new regions added to the Samsung TV Plus service, in addition to the possibility of reaching wider audiences through the broadening of channel line-up in territories already live.
During April and May Rakuten TV will roll out a total of 166 new channels in 16 markets through TV Plus.
With 20 premium channels, Rakuten TV will provide the full channel line-up exclusively for TV Plus as it expands its service into new territories. The roll-out started today with the launch of new channels in Denmark, Finland and Norway, followed by Belgium, Luxembourg, Portugal and Ireland planned for May.
Rakuten TV has also landed today at TV Plus in Sweden and the Netherlands with the launch of 7 premium channels.
In addition, alongside Rakuten TV's line-up already live on TV Plus in the UK, Spain, Germany, France, Italy, Austria and Switzerland, the Family channel became available in these markets on 14 April.
This launch will also broaden opportunities for advertisers, by extending reach to audiences across Europe. Samsung TV Plus sits alongside Rakuten Advertising's integrated portfolio, where publishers and advertisers can place ad-inventory across a variety of channels with the potential to reach more than 27M users across Europe. Through Rakuten TV channels available on TV Plus, brands will be able to run targeted campaigns to reach their potential new customers leveraging Rakuten Advertising’s powerful set of 1st party data and audience insights.
The enhanced line-up will provide the highest quality content at no cost. From top global channels, such as Africanews, Bloomberg TV, Bloomberg Quicktake, Euronews—the first live channel integrated into Rakuten TV's AVOD offer—Reuters and VENN, to a wide range of Rakuten TV's own themed channels curated by genres, from Action, Comedy, Drama, Spotlight, Family and Documentaries.
The new channels will be available on the TV Plus service in Samsung Smart TV devices from 2016 onwards in the UK, Spain, Germany, France, Italy, Austria, Switzerland; and in Samsung Smart TV devices from 2017 onwards in the rest of the markets.
Click here to download image: https://rak.box.com/s/5q7midm7sjgq2ldy86fnjdw3xe0bg3oo
About Rakuten TV
Rakuten TV is the first Video-On-Demand platform in Europe combining TVOD (Transactional video-on-demand), AVOD (Advertising video-on-demand) and SVOD (Subscription video-on-demand) services, providing users with a universe of content just one click away. While Rakuten TV's TVOD service provides a true cinematic experience with the latest new releases, the AVOD service offers a range of thematic channels for free, including Movies, Euronews, Kids TV, Viki, Documentaries and Rakuten Stories - a channel embodying Rakuten TV's original and exclusive content. On the subscription side, the platform provides the international SVOD service, Starzplay, as a premium content provider of movies and TV series.
Rakuten TV is available in 43 European territories and forms part of Rakuten Group, Inc. one of the worlds’ leading internet services companies, offering a wide variety of services for consumers and businesses, with a focus on e-commerce, fintech and digital content. Rakuten, headquartered in Japan, is also known for its partnership with FC Barcelona, the NBA, the Golden State Warriors, Davis Cup and Spartan Race.
www.rakuten.tv
About Rakuten Advertising
Rakuten Advertising provides advertising technology and consumer insights to the world’s leading brands and retailers. Working with agencies and brands around the world, Rakuten Advertising unites technology, client strategy and consumer insights to deliver advertising experiences that drive increased brand awareness and marketing performance. With access to Rakuten’s global audiences, media, content networks and consumer research, Rakuten Advertising creates the right conditions to reach new customers and sustain long-lasting loyalty. It is a division of Rakuten Inc. (4755: TOKYO), one of the world’s leading Internet service companies. The company is headquartered in San Mateo, CA, with offices in Australia, Singapore, Brazil, France, Germany, Ukraine, the United Kingdom and throughout the United States. Learn more at https://rakutenadvertising.com/
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry, and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com
About TV Plus
Samsung TV Plus gives viewers instant access to top news, sports, entertainment, and more. It's 100% free and doesn't require any downloads, sign-up, credit cards, subscriptions or additional devices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005300/en/
Contact information
Rakuten TV
Fernanda Perabeles – PR & Communications Specialist - fernanda.perabeles@rakuten.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom